VHIO

Breast Cancer & Melanoma Group

Javier Cortés

Medical Oncologists and Clinical Fellows
Judith Balmaña, Meritxell Bellet, Patricia Gómez, Esther Zamora, Leticia de Mattos, Eva Muñoz, Mafalda Oliveira, Vanesa Ortega, José Manuel Pérez, Aleix Prat, Cristina Saura, Jesús Soberino, Mª Jesús Vidal

SUMMARY

Our Breast Cancer Program continues to be one of the most active in Spain and one of the most renowned across Europe. In 2014, our 36 publications totaled an impact factor of 403.995, with a mean IF of 11.222. Notably, we published a newly proposed concept surrounding cancer research in January 2014 (published ahead of print, Nov 2013), in the highest impact factor journal, CA: A Cancer Journal for Clinicians (IF:164). In addition, we have initiated more than 20 new clinical trials and studies. Our group is not only committed to participating in clinical and preclinical studies, but also leads several – reflected by our representation of Steering Committees for some, and appointed international leaders for others. Our main areas of interest continue to center on the development of novel therapies and the search for mechanisms of resistance to current ones.

In 2014 we observed that combining eribulin with PI3K inhibitors might enhance the activity of both drugs, which has in turn opened up new possibilities for our patients – a phase Ib/II trial is currently underway.
-derived xenografts in collaboration with VHIO’s Preclinical Research Program. We have also been involved in the steering committees of the most relevant randomized Phase II and III clinical trials, and participated in some of the most important clinical trials — previously leading to the approval of drugs such as pertuzumab and eribulin. With regards to our circulating free DNA Program for genotyping and characterization we now have our first results which will be published next year. We have also provided more than 10 different new molecules in close collaboration with VHIO’s Experimental Therapeutics Group. In addition, more than 50% of our patients with metastatic melanoma have entered clinical trials.

PUBLICATIONS

Total 36.
Impact Factor 403.995
Average I.F. 11.222

  • Cortes J, Calvo E, Vivancos A, Perez-Garcia J, Recio JA, Seoane. J. New Approach to Cancer Therapy Based on a Molecularly Defined Cancer Classification. CA Cancer J Clin2014; 64(1):70-4.
  • Von Minckwitz G, Puglisi F, Cortes J, Vrdojak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, De Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15(11):1269-78.
  • Saura C, García-Saenz JA, Xu B, Harb W, Moroose R, Pluard T,Cortés J, Kiger C, Germa C, Wang K, Martin M, Baselga J, Kim SB. Safety and Efficacy of Neratinib in combination with Capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2014; 32(32):3626-33.
  • Baselga J, Cortes J, Im SA, Clark E, Ross G, Kiermaier A, Swain SM. Biomarker Analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014; 32(33):3753-61.
  • Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, elber RD; SOFT Investigators; International Breast Cancer Study Group. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. N Engl J Med 2015; Jan 29; 372(5):436-46. Epub 2014 Dec 11.

MAIN RESEARCH PROJECTS

  • Desvelando las vías moleculares que llevan al desarrollo de la carcinomatosis leptomeníngea.
    Predicción precoz de eficacia de la terapia endocrina en cáncer de mama: estudio piloto y validación con 18F-FES.
  • NEOBIG- Evaluating tumor simple preservation, integrity and performance: The Neobig pilot feasibility Study.
    The big molecular screening feasibility study: Testing the infrastructure and logistics of a molecular screening program.
  • Prevención de las recaídas mediante ejercicio, dieta y control de peso en pacientes con cáncer de mama.
  • Molecular screening platform for patients with advanced or metastatic breast cancer.
  • Sensibilidad a fármacos. Biopsias recogidas/Crecimiento en ratón.
  • Estudio traslacional de determinación en suero y plasma de BRAFV600 en pacientes con melanoma metastásico BRAFV600ç.
  • Cancer mama-BRCA: Estudio de mecanismos genéticos a terapias dirigidas.
  • Pacientes con Melanoma metastásico de recién diagnóstico. Seguimiento prospectivo de los pacientes BRAF mutados.
  • Detección de marcadores de muerte celular en pacientes con cáncer de mama tratadas con quimioterapia preoperatoria.
  • Predicción de respuesta a la quimioterapia neoadyuvante con docetaxel-carboplatino en cáncer de mama triple negativo en etapas II/III.
  • Molecular Quantification of ER Partners for Endocrine Response Prediction / Cuantificación molecular de proteínas relacionadas con el receptor de estrógeno para predecir respuesta endocrina.
  • Aceptación de la quimioterapia adyuvante en cáncer de mama precoz: Estudio del beneficio mínimo exigido por los pacientes en nuestro medio.